Advocacy intelligence hub — real-time data for patient organizations
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs2
FEIBA
(ANTI-INHIBITOR COAGULANT COMPLEX)Orphan drugstandardTakeda Pharmaceuticals America, Inc.
HYMPAVZI
(MARSTACIMAB-HNCQ)Orphan drugstandardPfizer Laboratories Div Pfizer Inc
NovoSeven
(Coagulation factor VIIa (recombinant))Orphan drugstandardNovo Nordisk, Inc.
12.1 Mechanism of Action The active ingredient in SEVENFACT is a recombinant analog of human Factor VIIa, a vitamin K-dependent coagulation factor. In...
Program Director, Clinical R&D
CSL Behring
Program Director
CSL Behring
Global Clinical Program Director
CSL Behring
Wolfhart Kreuz, PD Phd
Centre of Paediatrics III, Department of Haematology, Haemostaseology and Oncology, Comprehensive Care Centre for Thrombosis and Haemostasis, Johann-Wolfgang-Goethe-University Hospital
Marc Riedl, MD, MD
UC San Diego, La Jolla, California, United States
📍 SAN DIEGO, CA
Emel Aygören-Pürsün, MD
University Hospital Frankfurt - Goethe University, Frankfurt, Germany
View all Hereditary angioedema with normal C1Inh specialists →